Purpose To investigate serum vitamin D levels in patients newly diagnosed with non-Hodgkin lymphoma/diffuse large B-cell lymphoma (NHL-DLBCL), multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). Patients and methods We measured serum levels of vitamin D by ELISA in 103 patients prior to initiation of treatment, of whom 37 were diagnosed with MM, 32 with CLL and 34 with NHL-DLBCL. Results Suboptimal serum vitamin D levels (<30 ng/mL) were observed in all 103 patients. In 14 patients, serum vitamin D levels were between 20 and 30 ng/mL, while all other patients had vitamin D deficiency (<20 ng/mL). Severe vitamin D deficiency (<10 ng/mL) was observed in 32.3% of NHL-DLBCL patients, 28.1% of CLL patients and 81% of MM patients. Conclusion We observed low serum vitamin D levels in the majority of patients newly diagnosed with NHL-DLBCL, CLL and MM.

Aim: &#1058;&#1086; investigate the serum levels of vitamin D in newly diagnosed patients with multiple myeloma. Patients and methods: In this study we measured the serum levels of vitamin D in 37 patients (19 women, 18 men) at a median age of 68 years and a diagnosis of MM according to the International Myeloma Working Group (IMWG) criteria. The immunoassay tests used for the quantification of 25 (OH) &ndash; Vitamin D were original ELISA kits Immundiagnostic and the measurement was done before starting the treatment. Results: Serum levels below the optimum (<30 ng/ml) were recorded in all 37 patients. The median value of vitamin D was 4.3&plusmn;6.5 mg/ml, the maximum value measured was 24.7 mg/ml, which is below the lower limit of the reference value for deficiency. Conclusions: In this study, we found extremely low serum vitamin D levels in most of the newly diagnosed MM patients.

Lung cancer is a leading cause of cancer incidence and mortality worldwide with more than 2 million newly diagnosed cases in 2018. The disease is usually diagnosed in stage 3 or 4 with extensive clinical symptoms, which is a bad prognostic factor. Around 40% of patients with brain metastases are with a primary lung cancer, which shows the importance of this pathology. The main treatment option for inoperable lesions is radiosurgery, which can be done more than once in case of progression. This gives an opportunity to deliver a high dose in low volume with a high dose gradient while maintaining healthy tissues. Re-irradiation gives a change for good quality of life for patients with a long life expectancy. This case confirms that two and even three times re-irradiation with CyberKnife is an effective and safe therapeutic option for patients with brain metastases. Keywords: CyberKnife; radiosurgery; re-irradiation; brain metastases; lung cancer.

Acute myeloid leukemia (AML) is the most common form of acute leukemia in elderly patients. Over the past four decades the basic therapeutic armamentarium was the standard cytotoxic treatment. The new insights in understanding the pathogenesis of AML was the momentum that revolutionized the treatment landscape in AML. The last five years unprecedented growth has been seen in the number of target therapy drugs for the treatment of AML. These new drugs did not just have a clinical benefit as single agents but also have improved AML patient outcomes if combined with conventional cytotoxic therapy. Here, we review recent advances in target-based therapy for patients with AML focusing on their mechanism of action and the results from already published clinical trials.